CMC change impact assessment that shows every filing a plant change needs, and when each market will approve it
Every registration a change touches found, with each country's filing cited
See one case, screen by screen ↓It is the regulatory assessment of a manufacturing or quality change control: which registrations the change touches, what filing each country needs and when each agency will approve it. CMC Change Impact Assessment does that work with six agents that read the change, find every registration, quote each dossier, classify each market with its rule cited and plan the approval runway — for the regulatory CMC lead to decide and sign.
How to choose AI solutions for life sciences →
Updated
When a plant changes anything written into a registration — a site, a line, a supplier, a method, a limit, a shelf life — regulatory CMC has to decide, country by country, whether a filing is needed, which category, and when that agency will approve it. By hand that means pulling the registration list from RIM, opening each country's Module 3 or local approval to find whether the changed element is registered, looking up each country's classification, asking the affiliates, then building the filing plan in a spreadsheet.
The same change is classed differently in every market: a CBE-30 in the US, a Type IB variation in the EU, a partial change approval in Japan, a supplementary application in China. Miss one registration and changed material ships to a market that never approved it. Over-classify one and a market waits a year for nothing. And the plant often sets its implementation date without seeing the longest runway, so it runs two processes for years or holds the change.
Estimated split for five change controls in a week (Priya assesses 4–6), each across 21 markets: about 6.5 hours per change by hand and the 38-minute target with the solution, counted in 8-hour days.
Six agents read the change, find every registration, quote each dossier, classify each market and plan the runway; the regulatory CMC lead decides each market and the go-live date.
Northwind Bio makes Veltrimab, a monoclonal antibody registered in 21 markets as a 100 mg vial, a 150 mg prefilled syringe and a 300 mg pen. Priya Raman, its regulatory CMC lead, has a new drug-substance line to sign off — and a new filter supplier has just arrived from the QMS. Here is her morning, screen by screen, in the working solution.
CC-2026-0417 adds drug-substance Line B at Plant 3 — Leiden, a duplicate of Line A. The runway shows one bar per market from submission to expected approval: 36 registrations touched in 19 markets, 19 filings, the US CBE-30 and the EU and UK Type IB first, in Jan ’27. South Africa's Type II amendment is the longest runway at 30 months. South Korea and Mexico register a different site, so they are not affected.
Go-live suggestion: “Apr 2028 · Q2 2028 · 18 of 19 markets · 96.1% of volume — South Africa follows when approved.” The change control had planned Mar 2027, 13 months before the approvals.
The impact matrix colours each registration by what its country needs: 10 prior approval, 9 notify and wait, 2 not affected with a supply restriction, and 4 that need her call. The trace shows how the agents got there — the change reader in 4 s, the registration finder with 39 registrations in 21 markets, the dossier matcher quoting the registered text and finding 1 dossier out of date.
What needs you: “Türkiye · Type IB variation — Registered detail out of date — correct in the same filing.”
The registered text is quoted from the approval matters: “The approval matters for the manufacturing method state the culture step runs in one 12,000 L production line at Leiden.” The PMDA consultation record from March 2023 sits beside it. The classifier proposes a partial change approval — about 12 months, submitted Dec 2026, approved Dec 2027 — and names the alternative it considered.
“Alternative considered: Minor change notification — if PMDA agrees the line count is descriptive, not an approval matter. Ask Kenji Mori to confirm in a pre-consultation.”
Target submission is Dec 2026, once the Line B conformance batches and comparability report are ready. First approvals arrive in Jan 2027, 90% of volume in Feb 2028 and the last market, South Africa, in Jun 2029. The share-of-volume curve tops out at 96.5% — South Korea and Mexico must never receive the new material.
Dates come from three years of the company's own approval history and its sequencing rules — Saudi Arabia files after the EU decision.
The memo follows the company template: the change, the registered elements touched (3.2.S.2.1 and 3.2.S.2.2), and a filing table by market with the rule-book basis and expected approval. It stays a draft while markets are still proposed. Ten markets need prior approval, so Dr. Maya Chen adds a second approval after Priya signs.
“DRAFT · 21 markets still proposed” — only decided markets go into a signed memo.
CC-2026-0431 qualifies a second supplier of 0.2 µm PES sterilising-grade capsule filters for the final filtration of Veltrimab on filling Lines 1 and 2 at Cork — same pore rating, membrane and filter area. The plant has planned to implement in Apr 2027. Priya presses “Build the runway”: the change reader, registration finder, dossier matcher, rule classifier and runway planner run in turn.
Change reader: “add an alternate supplier of sterilising-grade filters (drug product) · 3.2.P.3.3 · 3.2.P.3.5.”
39 registrations in 21 markets, 21 filings: South Africa and Saudi Arabia implement and tell, most markets notify and wait, and South Korea, Singapore and China need prior approval. China's supplementary application runs to Feb 2028. The go-live line slides from the planned April to September.
“Sep 2027 · Q3 2027 · 20 of 21 markets · 95.0% of volume.” Planned in the change control: Apr 2027 — 5 months before the approvals.
The NMPA registration file registers the sterile filtration filter supplier in 3.2.P.3.3 and 3.2.P.3.5. China's rule book, v10 of Jun 2026, is quoted beside it. The proposal is a supplementary application (major), 80% confidence: about 14 months, submitted Dec 2026, approved Feb 2028. Li Wen is the affiliate.
Rule book · China: “A change of sterile filtration materials for a biological product is a major change: file a supplementary application with filter validation, extractables data and three batches; median review about 14 months.”
Priya chooses the split the runway planner suggested and sets Sep 2027 as the go-live date. The date is written back to the change control and supply planning is told. China keeps the current filter until NMPA approves in Feb 2028 — one date everywhere would have meant waiting until then.
“CC-2026-0431: go-live Sep 2027 written to the change control · supply planning told.”
When an assessment is approved, a task opens for each market with the category, the rule and the documents needed — owned by the affiliate, with a submit-by month and an expected approval. Kenji Mori, Li Wen, Ana Souza, Hanna Berg and Lena Ortiz work them from one tracker: 29 to prepare, 18 submitted and waiting.
The same change control, seen by the people who carry it — from the plant that raised it to the affiliate who files it.
Six agents read the change, find every registration, quote each dossier, classify each market and plan the runway; the regulatory CMC lead decides each market and the go-live date.
Reads each new change control from the QMS — description, justification and risk assessment — and states the product, presentations, sites, change type and the registered elements it may touch, with their CTD sections.
Finds every active registration of the product by presentation and country — including those under renewal — with the agency, licence number and the registered drug-substance and drug-product sites.
Opens each country's approved dossier section and quotes the exact text the change touches; marks registrations that do not include what changes, and flags dossiers that disagree with the approved change history.
Applies each country's approved rule book and past agency advice to propose the local filing category and its tier, with the rule cited, a confidence and the alternative it considered. Runs by region in parallel.
Estimates submission and approval dates per market from three years of company approval history and the sequencing rules, and suggests the go-live date: one date everywhere, or a split that lets a late market follow.
Writes the regulatory impact assessment memo in the company template from the decided markets, and opens one filing task per market with the category, rule, documents needed and target date.
Decides each market and sets the go-live; head of regulatory CMC co-signs big changes. The agents propose; a named person decides.
Ask in plain words about a change control, a market or a rule book — or say what to change. Every answer cites the passage behind it.
Why is Japan a partial change approval?
Because the line count is written into the Japanese approval. The approval matters say the culture step runs in one 12,000 L production line at Leiden, and in the March 2023 consultation PMDA said an added drug-substance line is handled as a partial change. A minor change notification only covers changes outside the approval matters. Confidence is 71% because PMDA could still treat the line count as descriptive; Kenji Mori can test that in a pre-consultation.
Why is the US a CBE-30 and not a PAS?
Line B duplicates Line A at the approved facility with the same equipment design, cell bank and process parameters. The US rule book puts that in a CBE-30 supplement — file at least 30 days before distributing. It would become a prior approval supplement only if the comparability data showed a difference in quality attributes. Confidence 93%.
Which markets are not affected?
Two: South Korea and Mexico. Both registrations list Plant 7 — Singapore as the only drug-substance site, so Line B at Leiden does not touch them and needs no filing. The catch is supply: Line B batches must never ship there. Together they are 3.5% of Veltrimab volume; Singapore keeps supplying them.
When can the filter change go live?
Sep 2027 (Q3 2027) in 20 of 21 markets — 95.0% of volume. China follows in Feb 2028: a supplementary application, about 14 months, so China keeps the current filter until NMPA approves. One date everywhere would be Feb 2028. The change control planned Apr 2027.
13 screens from the working solution, on its sample data. Pick one to see it large.
Who signs, when a second approval is needed and how a late market may follow are settings, on the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Signs the impact assessment | Priya Raman | Priya Raman · Dr. Maya Chen — with an electronic signature |
| Second approval when prior approval is needed in | 5 markets or more · Dr. Maya Chen | 3 · 5 · 8 markets · Dr. Maya Chen or Omar Haddad |
| Registered-detail corrections go to | Dana Okafor | Dana Okafor · Priya Raman |
| “Confirm the clear ones” includes proposals at or above | 80% | 90% · 85% · 80% — never automatic |
| Let a late market follow | 3+ months | 2+ · 3+ · 6+ months |
| Quote the registered text for every market | On | On · Off |
| Flag dossiers that disagree with today's process | On | On · Off |
| Sequencing rules | Saudi Arabia after EU · Singapore after EU and US | Add a rule in a sentence |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample data · “target” = the design goal, measured in the live solution · “estimated” = our estimate from the demo case · “typical” = published figures (ISPE, “An Evaluation of Postapproval CMC Change Timelines”, Pharmaceutical Engineering, Sep–Oct 2023 — about 16 months in North America and 39 in Africa and the Middle East to approve 90% of submissions, counted from the change's first approval anywhere). Regulatory context: ICH Q12; 21 CFR 314.70 and 601.12; Regulation (EC) No 1234/2008 as amended, with the EU variations classification guidelines applying from Jan 15, 2026. People, companies, products and plants named on this page are fictional — characters and sample data in the working solution.
It is the regulatory assessment of a manufacturing or quality change control: which registrations the change touches, what filing each country needs and when each agency will approve it. CMC Change Impact Assessment does that work with six agents that read the change, find every registration, quote each dossier, classify each market with its rule cited and plan the approval runway — for the regulatory CMC lead to decide and sign.
The rule classifier applies that country's approved rule book and past agency advice to the registered element the change touches, and proposes the local category — a CBE-30, a Type IB variation, a partial change approval — with the rule cited, a confidence and the alternative it considered. Below 75% confidence, or when a dossier disagrees with the change history, the market is flagged for a person.
Yes. Every active registration is listed, and the dossier matcher marks those that do not register what changes — in the demo, South Korea and Mexico register a different drug-substance site. A not-affected market always gets a supply restriction, so the new material never ships there.
The runway planner estimates submission and approval per market from three years of approval history and your sequencing rules. It suggests the earliest date the change can go live everywhere, or a split when a market approves more than a set gap after the rest — 3 months by default — so that market keeps the current process until it approves. The lead sets the date.
Rule books are kept as approved versions, and a rule watcher checks 21 agencies weekly. In the demo, the EU rule book v21 reflects the classification guidelines in force since Jan 15, 2026, approved by the head of regulatory CMC; open assessments are re-checked when a rule changes.
Yes. The agents propose and never file with an agency, edit a dossier or set the implementation date. The regulatory CMC lead decides every market, gives a reason for any changed category and signs; a second approval is needed when five or more markets require prior approval.
It reads change controls from the QMS and sends the approved assessment and dates back, reads registrations by product, presentation and country from registration records, and quotes Module 3 sections and local approval documents from the dossier archive. Filing tasks open as activities in the registration records.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your registrations, dossiers, country rule books and a sample of past change controls — and it goes live once every quality gate has passed. We will walk you through it on your own change controls first.
Every agency change reaches the right team within hours, with what changed marked.
1-min demoCTD Module 2 AuthoringModule 2 summaries drafted in weeks, every statement cited to its source.
1-min demoHealth Authority Query ResponseCited first drafts within hours, consistent with every past answer to every agency.
1-min demoWe'll run CMC Change Impact Assessment on a sample of your own recent change controls and registrations.